Video

Dr. Borgen on Advancements With HER2+ Breast Cancer

Author(s):

Patrick Borgen, MD

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

The view of HER2-positive breast cancer has changed, explains Borgen. Previously, HER2-positive breast cancer was thought to be the worst result a biopsy could detect, but targeted treatments have since revolutionized outcomes.

Related Videos
Jae Park, MD
David A. Braun, MD, PhD
Bradley McGregor, MD,
Francisco J. Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine – Lymphoma, director, Lymphoma Research, head, Lymphoma Translational Research Lab, associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Monica H. Vetter, MD
Ian Krop MD, PhD
Marco Davila, MD, PhD
Yvonne Mowery, MD, PhD, associate professor, Department of Radiation Oncology, UPMC Hillman Cancer Center/University of Pittsburgh, radiation oncologist, Mary Hillman Jennings Radiation Oncology, UPMC Shadyside
Related Content
FDA
January 20th 2025

FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

FDA
January 17th 2025

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Polly Niravath, MD
January 15th 2025

Clinical, Molecular Factors Correlate With pCR for Durvalumab/Trastuzumab/Pertuzumab in Early HER2+ Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 15th 2025

Neoadjuvant SHR-A1811 Produces pCRs in Early HER2+ Breast Cancer